Physician profile
Robbin C Oliver
NPI 1174870786
$2,440.26
in general payments reported to CMS, 2019-2025
16 companies · $950 in 2025
The $950 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $391 · 2024: $1,100 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.26 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.64 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $383.69 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $254.57 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $215.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $187.82 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $177.56 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $138.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $89.32 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.92 | 2024-2025 | Xifaxan |
| Pfizer INC. | $55.55 | 2024-2025 | |
| Amgen INC. | $46.20 | 2025 | Repatha, Otezla |
| Mylan Specialty L.P. | $43.34 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $41.17 | 2024 | Trintellix |
| Ascendis Pharma Endocrinology INC | $33.12 | 2025 | Yorvipath |
| Dexcom, INC. | $19.79 | 2025 | Dexcom G6 Transmitter |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.14 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robbin Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.